X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs PANACEA BIOTECH - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. PANACEA BIOTECH WOCKHARDT LTD./
PANACEA BIOTECH
 
P/E (TTM) x -22.0 -21.1 - View Chart
P/BV x 2.2 2.5 89.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT LTD.   PANACEA BIOTECH
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
PANACEA BIOTECH
Mar-14
WOCKHARDT LTD./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,012149 680.6%   
Low Rs53282 645.8%   
Sales per share (Unadj.) Rs355.984.1 422.9%  
Earnings per share (Unadj.) Rs-60.3-18.3 329.3%  
Cash flow per share (Unadj.) Rs-46.8-6.7 698.1%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.883.7 308.0%  
Shares outstanding (eoy) m110.6361.25 180.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.4 158.0%   
Avg P/E ratio x-12.8-6.3 202.9%  
P/CF ratio (eoy) x-16.5-17.2 95.7%  
Price / Book Value ratio x3.01.4 217.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3797,074 1,206.9%   
No. of employees `0006.32.8 227.4%   
Total wages/salary Rs m9,3711,449 646.6%   
Avg. sales/employee Rs Th6,295.01,874.1 335.9%   
Avg. wages/employee Rs Th1,498.3527.0 284.3%   
Avg. net profit/employee Rs Th-1,066.3-407.7 261.5%   
INCOME DATA
Net Sales Rs m39,3695,154 763.9%  
Other income Rs m1,202100 1,204.7%   
Total revenues Rs m40,5715,254 772.3%   
Gross profit Rs m18-766 -2.4%  
Depreciation Rs m1,495711 210.3%   
Interest Rs m2,5551,503 170.0%   
Profit before tax Rs m-2,830-2,881 98.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-3,5821,771 -202.3%   
Tax Rs m25717 1,529.8%   
Profit after tax Rs m-6,669-1,121 594.7%  
Gross profit margin %0-14.9 -0.3%  
Effective tax rate %-9.1-0.6 1,557.3%   
Net profit margin %-16.9-21.8 77.9%  
BALANCE SHEET DATA
Current assets Rs m33,7963,810 887.0%   
Current liabilities Rs m26,9178,365 321.8%   
Net working cap to sales %17.5-88.4 -19.8%  
Current ratio x1.30.5 275.7%  
Inventory Days Days79156 51.0%  
Debtors Days Days8967 132.7%  
Net fixed assets Rs m39,66414,480 273.9%   
Share capital Rs m55361 902.4%   
"Free" reserves Rs m27,968903 3,096.9%   
Net worth Rs m28,5225,127 556.3%   
Long term debt Rs m21,7315,832 372.6%   
Total assets Rs m81,62019,433 420.0%  
Interest coverage x-0.1-0.9 11.7%   
Debt to equity ratio x0.81.1 67.0%  
Sales to assets ratio x0.50.3 181.9%   
Return on assets %-5.02.0 -256.6%  
Return on equity %-23.4-21.9 106.9%  
Return on capital %-7.73.6 -211.0%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m9,8071,539 637.2%   
Fx outflow Rs m1,789942 189.9%   
Net fx Rs m8,019597 1,342.7%   
CASH FLOW
From Operations Rs m684599 114.2%  
From Investments Rs m6,302-438 -1,439.2%  
From Financial Activity Rs m-7,695-303 2,542.9%  
Net Cashflow Rs m-664-141 469.9%  

Share Holding

Indian Promoters % 74.5 74.5 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.6 383.3%  
FIIs % 7.7 1.3 592.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   67,757 10,259 660.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALKEM LABORATORIES  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (4QFY18); Net Profit Down 13.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, WOCKHARDT LTD. has posted a net profit of Rs 2 bn (down 13.4% YoY). Sales on the other hand came in at Rs 10 bn (up 17.9% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Sep 21, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - TORRENT PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS